Evidence map›Paper›PMID 42070965›Full record

Observational studyAddiction biology2026

Longitudinal Study of Plasma NFL and GFAP as Biomarkers of Alcohol Withdrawal-Associated Brain Injury.

Virgile Clergue-Duval, Frank Questel, Alexandra Dereux, Elodie Bouaziz-Amar, Julien Azuar, Romain Icick, Dorian Rollet, Vanessa Bloch, Jérôme Jeanblanc, Cynthia Marie-Claire and 5 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Addiction biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Virgile Clergue-DuvalDépartement de Psychiatrie et de Médecine Addictologique, APHP, GHU APHP.Nord- Université Paris Cité, Site Lariboisière Fernand-Widal, Paris, France.ORCID https://orcid.org/0000-0003-2803-8249
Frank QuestelDépartement de Psychiatrie et de Médecine Addictologique, APHP, GHU APHP.Nord- Université Paris Cité, Site Lariboisière Fernand-Widal, Paris, France.
Alexandra DereuxDépartement de Psychiatrie et de Médecine Addictologique, APHP, GHU APHP.Nord- Université Paris Cité, Site Lariboisière Fernand-Widal, Paris, France.
Elodie Bouaziz-AmarUniversité Paris Cité, INSERM, Optimisation thérapeutique en Neuropharmacologie OPTEN U1144, Paris, France.
Julien AzuarDépartement de Psychiatrie et de Médecine Addictologique, APHP, GHU APHP.Nord- Université Paris Cité, Site Lariboisière Fernand-Widal, Paris, France.ORCID https://orcid.org/0000-0002-7732-2265
Romain IcickDépartement de Psychiatrie et de Médecine Addictologique, APHP, GHU APHP.Nord- Université Paris Cité, Site Lariboisière Fernand-Widal, Paris, France.ORCID https://orcid.org/0000-0002-5078-4048
Dorian RolletDépartement de Psychiatrie et de Médecine Addictologique, APHP, GHU APHP.Nord- Université Paris Cité, Site Lariboisière Fernand-Widal, Paris, France.
Vanessa BlochUniversité Paris Cité, INSERM, Optimisation thérapeutique en Neuropharmacologie OPTEN U1144, Paris, France.
Jérôme JeanblancINSERM UMRS-1247 Groupe de Recherche Sur L'alcool et Les pharmacodépendances, Université de Picardie Jules Verne, Amiens, France.ORCID https://orcid.org/0000-0003-0353-2777
Cynthia Marie-ClaireUniversité Paris Cité, INSERM, Optimisation thérapeutique en Neuropharmacologie OPTEN U1144, Paris, France.
Jean-Louis LaplancheUniversité Paris Cité, INSERM, Optimisation thérapeutique en Neuropharmacologie OPTEN U1144, Paris, France.
Frank BellivierDépartement de Psychiatrie et de Médecine Addictologique, APHP, GHU APHP.Nord- Université Paris Cité, Site Lariboisière Fernand-Widal, Paris, France.
Claire PaquetUniversité Paris Cité, INSERM, Optimisation thérapeutique en Neuropharmacologie OPTEN U1144, Paris, France.ORCID https://orcid.org/0000-0002-2273-7316
Mickael NaassilaINSERM UMRS-1247 Groupe de Recherche Sur L'alcool et Les pharmacodépendances, Université de Picardie Jules Verne, Amiens, France.ORCID https://orcid.org/0000-0002-9788-0918
Florence VorspanDépartement de Psychiatrie et de Médecine Addictologique, APHP, GHU APHP.Nord- Université Paris Cité, Site Lariboisière Fernand-Widal, Paris, France.ORCID https://orcid.org/0000-0001-5168-3727

Funding

Fédération Hospitalo-Universitaire Network of Research in Substance Use DisordersINSERM research unit Optimisation thérapeutique en neuropharmacologie U1144Institut national de la santé et de la recherche médicale
6 · The paper itself

Abstract

Plasma neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), tau protein and ubiquitin carboxy-terminal hydrolase L1 (UCHL1) are candidate biomarkers of alcohol withdrawal (AW)-associated brain toxicity, as they are biomarkers of axonal, neuronal or glial injury. The aim of this study was to investigate the changes of these biomarkers during AW in patients with severe alcohol use disorder (AUD). Plasma NFL, GFAP, tau and UCHL1 levels were measured, with SIMOA, at three times: on Day 1 (T1), on Day 3 or 4 (T2) and on Day 13, 14 or 15 (T3) of AW. They were analysed with a linear mixed model adjusted for age, sex and body mass index. Changes in these levels according to AW symptom severity were evaluated. Twenty-four inpatients with severe AUD were included: 20 men (83.3%), aged 47.4 years [±11.3], with symptoms requiring a median equivalent-diazepam dose of 0.81 mg/kg at T1. A significant increase was observed for NFL level from T1 to T2 (β = 0.349, p = 0.035), but not for GFAP, tau or UCHL1 levels. In AW symptom severity analyses, a significant positive association was found with equivalent-diazepam dose required × T1-T2 time interaction factor for NFL (β = 0.161, p = 0.028) and for GFAP (β = 0.400, p = 9.9 × 10

Indexed as

AlcoholismBrain InjuriesGlial Fibrillary Acidic ProteinNeurofilament ProteinsSubstance Withdrawal SyndromeAdultBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle Agedtau ProteinsUbiquitin ThiolesteraseBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteinneurofilament protein LNeurofilament Proteinstau ProteinsUbiquitin ThiolesteraseUCHL1 protein, humanalcohol‐related brain damagealcohol‐related disorderbiomarkersglial fibrillary acidic proteinhyperglutamatergicnervous system disordersneurofilament light chain

Identifiers

PMID42070965
PMCPMC13135891

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.